1. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy
- Author
-
Mark J. Smyth, Yuting Ma, Guido Kroemer, Oliver Kepp, Laurence Zitvogel, Takahiro Yamazaki, Lorenzo Galluzzi, and Heng Yang
- Subjects
Anthracycline ,dendritic cell ,Immunology ,T cells ,calreticulin ,Immune system ,immunogenic cell death ,medicine ,Immunology and Allergy ,Doxorubicin ,Interferon gamma ,Original Research ,interferon γ ,biology ,business.industry ,apoptosis ,Dendritic cell ,Oncology ,biology.protein ,Cancer research ,Immunogenic cell death ,Tumor necrosis factor alpha ,Antibody ,business ,medicine.drug - Abstract
The antineoplastic effects of anthracyclines have been shown to rely, at least in part, on a local immune response that involves dendritic cells (DCs) and several distinct subsets of T lymphocytes. Here, we show that the administration of anthracyclines to mice bearing established neoplasms stimulates the intratumoral secretion of tumor necrosis factor α (TNFα). However, blocking the TNFα/TNF receptor (TNFR) system by three different strategies—namely, (1) neutralizing antibodies, (2) etanercept, a recombinant protein in which TNFR is fused to the constant domain of an IgG1 molecule, and (3) gene knockout—failed to negatively affect the therapeutic efficacy of anthracyclines in three distinct tumor models. In particular, TNFα-blocking strategies did not influence the antineoplastic effects of doxorubicin (a prototypic anthracycline) against MCA205 fibrosarcomas growing in C57BL/6 mice, F244 sarcomas developing in 129/Sv hosts and H2N100 mammary carcinomas arising in BALB/c mice. These findings imply that, in contrast to other cytokines (such as interleukin-1β, interleukin-17 and interferon γ), TNFα is not required for anthracyclines to elicit therapeutic anticancer immune responses.
- Published
- 2013